EFFECTS OF NANOCURCUMIN IN RATS WITH DIABETES INDUCED WITH STREPTOZOTOCIN AND NICOTINAMIDE: MRNA EXPRESSION OF B-TYPE NATRIURETIC PEPTIDE
DOI:
https://doi.org/10.22159/ijap.2018.v10s1.38Keywords:
B-type natriuretic peptide-45, Nanocurcumin, Nicotinamide, StreptozotocinAbstract
Objective: This study aimed to determine the effects of nanocurcumin on cardiomyopathy, assessed by the expression of B-type natriuretic peptide
(BNP) mRNA in heart tissue.
Methods: Type 2 diabetic rats were induced with streptozotocin and nicotinamide. Nanocurcumin was orally administered (100 mg/kg/day)
for 30 days. BNP-45 mRNA expression in the heart tissue was measured using quantitative reverse transcription-polymerase chain reaction and
calculated using the Livak method.
Results: BNP-45 levels increased significantly (p<0.05) in diabetic rats compared with the normal group. Nanocurcumin treatment at a dose of
100 mg/kg for 30 days significantly decreased BNP-45 expression levels (p<0.05) compared with diabetic rats without treatment.
Conclusion: Nanocurcumin may be beneficial in inhibiting the progression of diabetic cardiomyopathy by suppressing the expression of BNP-45.
Downloads
References
Purnamasari D. Texbook of Internal Medicine. Jakarta: Internal
Publishing; 2014. p. 2323.
Indonesian Ministry of Health. Situation and Analysis of Diabetes.
Jakarta: Data and Information Center; 2014.
Waspadji S. Textbook of Internal Medicine. Jakarta: Internal Publishing; 2014.
Powers AC, In Harrison’s Endocrinology. 17th ed. New York: McGraw-
Hill; 2008. p. 267.
Shahab A. Texbook of Internal Medicine. Jakarta: Internal Publishing;
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE,
Duc P, et al. Rapid measurement of B-type natriuretic peptide in the
emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G.
Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and
management. World J Diabetes 2013;4:177-89.
Takei Y. B-Type natriuretic peptide (BNP) and C-type natriuretic
peptide (CNP). In: Handbook of Biologically Active Peptides. Vol. 10.
London: Elsevier; 2006. p. 805-12.
Jurenka JS. Anti-inflammatory properties of curcumin, a major
constituent of curcuma longa: A review of preclinical and clinical
research. Altern Med Rev 2009;14:141-53.
Jayaprakasha GK, Rao LJ, Sakariah KK. Antioxidant activities of
curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food
Chem 2006;98:720-4.
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R,
Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of
Type 2 diabetes. Diabetes Care 2012;35:2121-7.
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB.
Bioavailability of curcumin: Problems and promises. Mol Pharm
;4:807-18.
Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and
drug delivery Part 1: Background and applications. Trop J Pharm Res
;8:265-74.
Wang YJ, Lin HY, Wu CH, Liu DM. Forming of demethoxycurcumin
nanocrystallite-chitosan nanocarrier for controlled low dose cellular
release for inhibition of the migration of vascular smooth muscle cells.
Mol Pharm 2012;9:2268-79.
Nainggolan H. The Effect of Oral Nanokurkumin on Mice with Diabetic
Cardiomyopathy Focused on Oxidative Stress Resistance. Jakarta:
Pharmacology and Therapeutics Departement Faculty of Medicine
Universitas Indonesia; 2016.
Ferdinal F, Suyatna FD, Wanandi SI, Sadikin M. Expression of
B-type natriuretic peptide-45 (BNP-45) gene in the ventricular
myocardial induced by systemic chronic hypoxia. Acta Med Indones
;41:136‑43.
Published
How to Cite
Issue
Section
